clinical trial · NCT04662281
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Postherpetic NeuralgiaPlaceboLX9211
brief summary
Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.
started
Dec 10, 2020
primary completion
Nov 18, 2022
completion
Dec 28, 2022
last updated
Feb 13, 2026
official title
A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol